Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. However, not all innovations are equal and nor do they follow a constant upward trend.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

XTalks

AUGUST 17, 2020

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. Cell-Based Immunotherapy vs. Immune Biologics. Immunotherapy involves leveraging components of the immune system (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. In these cases B cell depletion is a feature, not a bug.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

XTalks

NOVEMBER 29, 2024

Their pipeline includes P-BCMA-ALLO1, a promising therapy targeting multiple myeloma that has received Regenerative Medicine Advanced Therapy designation and Orphan Drug designation from the US Food and Drug Administration (FDA). Poseida’s expertise in donor-derived, allogeneic CAR-T therapies offers a transformative edge.

Gene Therapy 100

Gene Therapy Gene Gene Editing Genetic Engineering 100